WHO: Christopher L. Amling, M.D., AUA Public Media Committee David Penson, M.D., University of Southern California, Norris Cancer Center
WHAT: Data on Provenge, a new therapeutic prostate cancer vaccine, will be presented during the Plenary Session on Tuesday, May 22. Presented David Penson, M.D. will meet with interested members of the media in advance of the presentation to provide background and perspective on this new therapy for metastatic prostate cancer.
WHEN: Monday, May 21, 2007 3:00 p.m. PDT
WHERE: AUA Press Suite (Mezzanine Show Offices A and B), Anaheim Convention Center
HOW: Access to this special session is free to all credentialed media representatives covering the meeting. Dial-in information for reporters interested in covering remotely is available by calling 714-765-2033.
About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is the pre-eminent professional organization for urologists, with more than 15,000 members throughout the world. An educational nonprofit organization, the AUA pursues its mission of fostering the highest standards of urologic care by carrying out a wide variety of programs for members and their patients, including UrologyHealth.org, an award-winning on-line patient education resource, and the American Urological Association Foundation, Inc., formerly AFUD.